Kathryne Rupley, DPM
Podiatrist · Fresno, CANPI 1932203536
Payments from drug & device makers
Across 64 payments — averaging $56.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$960
- Medtronic$781
- Nevro Corp.$462
- Stryker$303
- Averitas Pharma Inc.$165
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- plus $811 from 12 others
What the payments were for
- Speaking & faculty fees$1253%
- Food & beverage$3,47495%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 22 | $960 |
| Medtronic | 9 | $781 |
| Nevro Corp. | 10 | $462 |
| Stryker | 4 | $303 |
| Averitas Pharma Inc. | 3 | $165 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $162 |
| Biotronik NRO, Inc. | 1 | $125 |
| Angiodynamics, Inc. | 1 | $111 |
| AbbVie | 1 | $93 |
| Orthofix Medical, Inc. | 2 | $83 |
| Boston Scientific | 1 | $83 |
| Smith+Nephew | 3 | $74 |
| Melinta Therapeutics, LLC | 1 | $71 |
| Idorsia Pharmaceuticals US Inc | 1 | $63 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $34 |
| BD | 1 | $31 |
| Paratek Pharmaceuticals, Inc. | 1 | $29 |
| Solventum Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apligraf$556
- PURAPLY WOUND MATRIX$271
- Affinity$271
- Dermagraft$250
- Puraply/Affinity/NuTech$250
- RELISTOR$162
- GRAVITY$153
- Senza$141
- Accurian$138
- Omnia$135
- INTELLIS ADAPTIVESTIM$131
- Qutenza$125
- Prospera$125
- ORTHOLOC 2 LAPIFUSE$105
How this compares
$3,643 in reported general payments places this provider in the 75th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 15 | $494 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 77 | $446 |
| Doxycycline Hyclate | 26 | $158 |
| Clindamycin Hcl | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Fresno
- Shawn CazzellFresno$788K
- Emmy OjiFresno$29K
- Robert BuckenbergerFresno$21K
- Fardin HakakianTarzana$2.8M
- David GuzmanNapa$2.1M
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.6M
- David ArmstrongLos Angeles$1.4M
- Dean VayserCarlsbad$1.2M
- Robert KleimanCalexico$913K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.